Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 236-244

  De Luca, Andrea ^a,b   Marazzi, Maria Cristina ^c   Mancinelli, Sandro ^d   Ceffa, Susanna ^e   Altan, Anna Maria Doro ^d   Buonomo, Ersilia ^d   Prosperi, Mattia Carlo Felice ^a,f   Pedruzzi, Barbara ^a   Noorjehan, Abdul Majid ^g   Scarcella, Paola ^d   Liotta, Giuseppe ^d   Palombi, Leonardo ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c LUMSA UNIVERSITY   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e DREAM Program Community of Sant'Egidio   (Italy)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g Maputo and Machava Health Center   (Mozambique)

Author keywords

Adherence; Antiretroviral therapy; Retention; Second line therapy; Sub Saharan Africa; Viral load

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; STAVUDINE; VIRUS RNA;

ADOLESCENT; ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84859777430     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824276e9     Document Type: Article

References (34)

1. UNAIDS/WHO. AIDS epidemic update December 2009. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization(WHO), December 2009. Available at: http: //data.unaids.org/pub/Report/2009/JC1700-Epi-Update- 2009-en.pdf.
2. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviraltreated patients in Sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48: 115-122.
3. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367: 817-824.
4. Coutinho A, Mermin J, Ekwaru J, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 125.
5. Dart trial team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized noninferiority trial. Lancet. 2009;375: 123-131.
6. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371: 1443-1451. (Pubitemid 351635534)
7. Bendavid E, Young SD, Katzenstein DA, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: A southern African analysis. Arch Intern Med. 2008;168: 1910.
8. Ndembi N, Goodall RL, Dunn DT, et al. Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis. 2010;201: 106-113.
9. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9: 409-417.
10. Kantor R, Diero L, DeLong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49: 454-462.
11. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22: 1971-1977.
12. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23: 697-700.
13. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007; 44: 128-134. (Pubitemid 44968997)
14. Moore DM, Mermin J. Monitoring antiretroviral failure in resource-poor settings. Lancet. 2008;371: 1396-1397. (Pubitemid 351611658)
15. Lawn SD, Bekker LG, Calmy A, et al. Monitoring of antiretroviral therapy in low-resource settings. Lancet. 2008;372: 287-288. (Pubitemid 352037426)
16. Elliott JH, Lynen L, Calmy A, et al. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS. 2008;22: 2053-2067.
17. Chêne G, Sterne JA, May M, et al. Antiretroviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362: 679-686.
18. Grabar S, Le Moing V, Goujard C, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr. 2005;39: 284-292. (Pubitemid 40923207)
19. Lanoy E, May M, Mocroft A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009;23: 2199-2208.
20. San Lio MM, Carbini R, Germano P, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis. 2008;46: 1609-1616. (Pubitemid 351706745)
21. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23: 335-342.
22. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368: 505-510. (Pubitemid 44142772)
23. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendation for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
24. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364: 51-62.
25. World Health Organization. Rapid Advice. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organization; 2009. Available at: http: //www.who.int/hiv/pub/arv/rapid-advice- art.pdf. Accessed December 16, 2011.
26. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006;3: e417.
27. van Zyl GU, Preiser W, Potschka S, et al. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis. 2011;52: 264-270.
28. Rosenblum M, Deeks S, Van Der Laan M, et al. The risk of virologic failure decreases with duration of HIV suppression at greater than 50% adherence to antiretroviral therapy. PLoS ONE. 2009;4: e7196.
29. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4: e298.
30. Brinkhof WG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE. 2009;4: e5790.
31. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51: 65-71.
32. Losina E, Touré T, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d'Ivoire appraisal. PLoS Med. 2009;6: e1000173.
33. The Clinton Foundation HIV/AIDS initiative. Antiretroviral (ARV) price list. 2009. Available at: http: //www.clintonfoundation.org/files/ chaiarvpricelistaugust2009english.pdf. Accessed December 16, 2011.
34. World Health Organizations. Transaction Prices for AntiretroviralMedicines and HIV Diagnostics From 2008 to October 2009. A Summary Report From the Global Price Reporting Mechanism. Geneva, Switzerland; WHO: 2009. Available at: http: //www.who.int/hiv/amds/GPRMsummary ReportNov2009.pdf. Accessed December 16, 2011.